{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:55:39Z","timestamp":1790474139126,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T00:00:00Z","timestamp":1467072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.jtho.2016.04.028","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T18:16:39Z","timestamp":1469211399000},"page":"1246-1262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["Consensus Report of the 2015 Weinman International Conference on Mesothelioma"],"prefix":"10.1016","volume":"11","author":[{"given":"Michele","family":"Carbone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Kanodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrey","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Boffetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"de Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Umran","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Gavett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gualtieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hesdorffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Masten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Pira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavitt Alida","family":"Woodard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakun","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.04.028_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008","volume":"19","author":"Henley","year":"2013","journal-title":"Int J Occup Environ Health"},{"key":"10.1016\/j.jtho.2016.04.028_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.15585\/mmwr.mm6254a3","article-title":"Summary of notifiable noninfectious conditions and disease outbreaks: surveillance for cancer incidence and mortality\u2014United States, 2011","volume":"62","author":"Singh","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jtho.2016.04.028_bib3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2016.04.028_bib4","first-page":"523","article-title":"Extrapleural pneumonectomy and extended pleurectomy\/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach","volume":"1","author":"Rusch","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2016.04.028_bib5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib6","series-title":"Cancer Epidemiology and Prevention","first-page":"659","article-title":"Pleural and peritoneal neoplasms","author":"Boffetta","year":"2006"},{"key":"10.1016\/j.jtho.2016.04.028_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.jtho.2016.04.028_bib8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1289\/ehp.1002845","article-title":"Global magnitude of reported and unreported mesothelioma","volume":"119","author":"Park","year":"2011","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jtho.2016.04.028_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6602307","article-title":"The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050","volume":"92","author":"Hodgson","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(10)60251-6","article-title":"Health experts concerned over India's asbestos industry","volume":"375","author":"Burki","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2016.04.028_bib11","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1073\/pnas.1105887108","article-title":"Erionite exposure in North Dakota and Turkish villages with mesothelioma","volume":"108","author":"Carbone","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2016.04.028_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2068","article-title":"A\u00a0mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes","volume":"7","author":"Carbone","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib13","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1158\/0008-5472.CAN-05-4642","article-title":"Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey","volume":"66","author":"Dogan","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib14","first-page":"169","article-title":"First experimental evidence of peritoneal and pleural mesotheliomas induced by fluoro-edenite fibres present in Etnean volcanic material from Biancavilla (Sicily, Italy)","volume":"9","author":"Soffritti","year":"2004","journal-title":"Eur J Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1289\/ehp.1002862","article-title":"Pleural mesothelioma in New Caledonia: associations with environmental risk factors","volume":"119","author":"Baumann","year":"2011","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jtho.2016.04.028_bib16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2016.04.028_bib17","doi-asserted-by":"crossref","first-page":"e1005633","DOI":"10.1371\/journal.pgen.1005633","article-title":"Combined genetic and genealogic studies uncover a large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common ancestor from the 1700s","volume":"11","author":"Carbone","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jtho.2016.04.028_bib18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/13816810.2015.1010734","article-title":"Analysis of BAP1 germline gene mutation in young uveal melanoma patients","volume":"36","author":"Cebulla","year":"2015","journal-title":"Ophthal Genet"},{"key":"10.1016\/j.jtho.2016.04.028_bib19","doi-asserted-by":"crossref","first-page":"e35295","DOI":"10.1371\/journal.pone.0035295","article-title":"Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families","volume":"7","author":"Njauw","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2016.04.028_bib20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ajhg.2013.04.012","article-title":"Germline BAP1 mutations predispose to renal cell carcinomas","volume":"92","author":"Popova","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jtho.2016.04.028_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cge.12501","article-title":"A\u00a0recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma","volume":"88","author":"Wadt","year":"2015","journal-title":"Clinic Genet"},{"key":"10.1016\/j.jtho.2016.04.028_bib22","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Abdel-Rahman","year":"2011","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jtho.2016.04.028_bib23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2016.04.028_bib24","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/1541-7786.MCR-13-0111","article-title":"A\u00a0novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma","volume":"11","author":"Farley","year":"2013","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/cge.12472","article-title":"Germline BAP1 mutations predispose also to multiple basal cell carcinomas","volume":"88","author":"de la Fouchardiere","year":"2015","journal-title":"Clin Genet"},{"key":"10.1016\/j.jtho.2016.04.028_bib26","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/onc.2015.243","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma","volume":"35","author":"Napolitano","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2016.04.028_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/(SICI)1097-4644(20000201)76:2<189::AID-JCB3>3.0.CO;2-J","article-title":"Simian virus 40 and human tumors: it is time to study mechanisms","volume":"76","author":"Carbone","year":"1999","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.jtho.2016.04.028_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3816\/CLC.2003.n.031","article-title":"Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40","volume":"5","author":"Gazdar","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2217\/lmt.15.21","article-title":"Causes and pathophysiology of malignant pleural mesothelioma","volume":"4","author":"Jean","year":"2015","journal-title":"Lung Cancer Management"},{"key":"10.1016\/j.jtho.2016.04.028_bib30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(00)04013-7","article-title":"Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey","volume":"357","author":"Roushdy-Hammady","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2016.04.028_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer\u00a0syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jtho.2016.04.028_bib32","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2016.04.028_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.humpath.2014.10.015","article-title":"BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations","volume":"46","author":"Piris","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2016.04.028_bib34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib36","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2016.04.028_bib37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2016.04.028_bib39","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1038\/ncomms6128","article-title":"Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis","volume":"5","author":"Lee","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2016.04.028_bib40","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1128\/MCB.00396-10","article-title":"The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression","volume":"30","author":"Yu","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jtho.2016.04.028_bib41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2016.04.028_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12013-011-9184-6","article-title":"An emerging model for BAP1's role in regulating cell cycle progression","volume":"60","author":"Eletr","year":"2011","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.jtho.2016.04.028_bib43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2016.04.028_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2016.04.028_bib45","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","article-title":"BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization","volume":"68","author":"Ventii","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib46","doi-asserted-by":"crossref","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","article-title":"The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1","volume":"284","author":"Machida","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtho.2016.04.028_bib47","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/MCB.01517-08","article-title":"Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1","volume":"29","author":"Misaghi","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jtho.2016.04.028_bib48","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1158\/0008-5472.CAN-14-0221","article-title":"Deubiquitination of gamma-tubulin by BAP1 prevents chromosome instability in breast cancer cells","volume":"74","author":"Zarrizi","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib49","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.molcel.2014.03.002","article-title":"Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O","volume":"54","author":"Mashtalir","year":"2014","journal-title":"Mol Cell"},{"key":"10.1016\/j.jtho.2016.04.028_bib50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib51","doi-asserted-by":"crossref","first-page":"28643","DOI":"10.1074\/jbc.M115.661553","article-title":"The BAP1\/ASXL2 histone H2A deubiquitinase complex regulates cell proliferation and is disrupted in cancer","volume":"290","author":"Daou","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtho.2016.04.028_bib52","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1039\/b810541n","article-title":"10th anniversary critical review: naturally occurring asbestos","volume":"10","author":"Harper","year":"2008","journal-title":"J Environ Monit"},{"key":"10.1016\/j.jtho.2016.04.028_bib53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1130\/G36199.1","article-title":"Genesis and health risk implications of an unusual occurrence of fibrous NaFe3+-amphibole","volume":"43","author":"Metcalf","year":"2015","journal-title":"Geology"},{"key":"10.1016\/j.jtho.2016.04.028_bib54","unstructured":"Clear Creek Management Area, Asbestos Exposure and Human Health Risk Assessment, U.S. EPA Region 9 Report. 2008. http:\/\/yosemite.epa.gov\/opa\/admpress.nsf\/2dd7f669225439b78525735900400c31\/8fa475ab3f99c22a8525743b007d88d1!opendocument. Accessed June 14, 2016."},{"key":"10.1016\/j.jtho.2016.04.028_bib55","unstructured":"Addison J, Davies LST, Robertson A, Wiley RJ. The Release of Dispersed Asbestos Fibres from Soils. Institute of Occupational Medicine Historical Research Report TM\/88\/14. Published 1988. http:\/\/www.iom-world.org\/pubs\/IOM_TM8814.pdf. Accessed June 14, 2016."},{"key":"10.1016\/j.jtho.2016.04.028_bib56","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.2138\/am-2003-11-1239","article-title":"The composition and morphology of amphiboles from the Rainy Creek Complex, near Libby, Montana","volume":"88","author":"Meeker","year":"2003","journal-title":"American Mineralogist"},{"key":"10.1016\/j.jtho.2016.04.028_bib57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/sca.20276","article-title":"Quantitative characterization of the mesothelioma-inducing erionite series minerals by transmission electron microscopy and energy dispersive spectroscopy","volume":"34","author":"Dogan","year":"2012","journal-title":"Scanning"},{"key":"10.1016\/j.jtho.2016.04.028_bib58","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1289\/ehp.6346","article-title":"Radiographic abnormalities and exposure to asbestos-contaminated vermiculite in the community of Libby, Montana, USA","volume":"111","author":"Peipins","year":"2003","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jtho.2016.04.028_bib59","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.2136\/sssaj2013.05.0183","article-title":"Naturally occurring asbestos: potential for human exposure, Southern Nevada, USA","volume":"77","author":"Buck","year":"2013","journal-title":"Soil Science Society of America Journal"},{"key":"10.1016\/j.jtho.2016.04.028_bib60","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1158\/0008-5472.CAN-04-0255","article-title":"Modern criteria to establish human cancer etiology","volume":"64","author":"Carbone","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib61","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/08958370802291304","article-title":"Lung fiber burden in the Nottingham gas mask cohort","volume":"21","author":"Berry","year":"2009","journal-title":"Inhal Toxicol"},{"key":"10.1016\/j.jtho.2016.04.028_bib62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/toxsci\/kfs249","article-title":"Sumas Mountain chrysotile induces greater lung fibrosis in Fischer344 rats than Libby amphibole, El Dorado tremolite, and Ontario ferroactinolite","volume":"130","author":"Cyphert","year":"2012","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jtho.2016.04.028_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/15287394.2015.1099123","article-title":"Long-term toxicity of naturally occurring asbestos in male Fischer 344 rats","volume":"79","author":"Cyphert","year":"2016","journal-title":"J\u00a0Toxicol Environ Health. A"},{"key":"10.1016\/j.jtho.2016.04.028_bib64","doi-asserted-by":"crossref","unstructured":"Larson D, Powers A, Ambrosi JP, et al. Investigating palygorskite's role in the development of mesothelioma in southern Nevada: insights into fiber-induced carcinogenicity. J Toxicol Environ Health, part B. In press.","DOI":"10.1080\/10937404.2016.1195321"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2016.04.028_bib65","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1289\/ehp.97105s51257","article-title":"Pleural macrophage recruitment and activation in asbestos-induced pleural injury","volume":"105","author":"Choe","year":"1997","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jtho.2016.04.028_bib66","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","article-title":"Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-alpha signaling","volume":"183","author":"Qi","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtho.2016.04.028_bib67","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.1073\/pnas.0604008103","article-title":"TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis","volume":"103","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2016.04.028_bib68","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2016.04.028_bib69","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10937404.2011.556051","article-title":"Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases","volume":"14","author":"Huang","year":"2011","journal-title":"J\u00a0Toxicol Environ Health B Crit Rev"},{"key":"10.1016\/j.jtho.2016.04.028_bib70","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1073\/pnas.0808816106","article-title":"Activated TNF-alpha\/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice","volume":"106","author":"Altomare","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2016.04.028_bib71","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1165\/ajrcmb.19.2.3111","article-title":"Asbestos fibers and interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells","volume":"19","author":"Choe","year":"1998","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jtho.2016.04.028_bib72","first-page":"1001","article-title":"Transforming growth factor-beta-induced protein (TGFBI) suppresses mesothelioma progression through the Akt\/mTOR pathway","volume":"39","author":"Wen","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib73","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/oemed-2015-103074","article-title":"Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden","volume":"73","author":"Gilham","year":"2016","journal-title":"Occupat Environ Med"},{"key":"10.1016\/j.jtho.2016.04.028_bib74","first-page":"479","article-title":"The wild rat as sentinel animal in the environmental risk assessment of asbestos pollution: a pilot study","author":"Ardizzone","year":"2014","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.jtho.2016.04.028_bib75","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/(SICI)1097-0274(199611)30:5<579::AID-AJIM5>3.0.CO;2-O","article-title":"Comparison of measures of exposure to asbestos in former crocidolite workers from Wittenoom Gorge, W. Australia","volume":"30","author":"de Klerk","year":"1996","journal-title":"Am J Ind Med"},{"key":"10.1016\/j.jtho.2016.04.028_bib76","first-page":"625","article-title":"Deposition and clearance of chrysotile asbestos","volume":"38","author":"Churg","year":"1994","journal-title":"Ann Occup Hyg"},{"key":"10.1016\/j.jtho.2016.04.028_bib77","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/(SICI)1097-0274(199904)35:4<401::AID-AJIM12>3.0.CO;2-4","article-title":"Inferences on the kinetics of asbestos deposition and clearance among chrysotile miners and millers","volume":"35","author":"Finkelstein","year":"1999","journal-title":"Am J Ind Med"},{"key":"10.1016\/j.jtho.2016.04.028_bib78","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/PAT.0b013e3283631cce","article-title":"Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy","volume":"45","author":"Lee","year":"2013","journal-title":"Pathology"},{"key":"10.1016\/j.jtho.2016.04.028_bib79","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/oem.2005.023200","article-title":"The French National Mesothelioma Surveillance Program","volume":"63","author":"Goldberg","year":"2006","journal-title":"Occupat Environ Med"},{"key":"10.1016\/j.jtho.2016.04.028_bib80","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib81","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","article-title":"Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma","volume":"72","author":"Jube","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib82","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/MCG.0b013e318297fa65","article-title":"Serum HMGB1 as a Diagnostic marker for malignant peritoneal mesothelioma","volume":"47","author":"Tabata","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jtho.2016.04.028_bib83","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-13-205","article-title":"Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma","volume":"13","author":"Tabata","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib84","doi-asserted-by":"crossref","unstructured":"Napolitano A, Antoine DJ, Pellegrini L, et\u00a0al. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients [e-pub ahead of print]. Clin Cancer Res. http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-15-1130, accessed June 14, 2016.","DOI":"10.1158\/1078-0432.CCR-15-1130"},{"key":"10.1016\/j.jtho.2016.04.028_bib85","doi-asserted-by":"crossref","first-page":"e46091","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"Ostroff","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2016.04.028_bib86","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2016.04.028_bib87","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib88","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.04.028_bib89","doi-asserted-by":"crossref","first-page":"11074","DOI":"10.1200\/jco.2008.26.15_suppl.11074","article-title":"Evaluation of plasma osteopontin as early detection and prognostic marker in malignant pleural mesothelioma","volume":"26","author":"Beck","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib90","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2011.02.007","article-title":"Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma\u2014which is best?","volume":"74","author":"Creaney","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib91","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/JTO.0b013e31821e1c08","article-title":"Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma","volume":"6","author":"Cristaudo","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib92","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/172460081002500307","article-title":"Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma","volume":"25","author":"Cristaudo","year":"2010","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.jtho.2016.04.028_bib93","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 As a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.04.028_bib94","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.7314\/APJCP.2015.16.4.1403","article-title":"Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma","volume":"16","author":"Kaya","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jtho.2016.04.028_bib95","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.jtho.2016.04.028_bib96","first-page":"5517","article-title":"YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis","volume":"33","author":"Corradi","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib97","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis","volume":"113","author":"Kirschner","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib98","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejcdt.2013.10.004","article-title":"Role of fibulin-3 in the diagnosis of malignant mesothelioma","volume":"63","author":"Agha","year":"2014","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"10.1016\/j.jtho.2016.04.028_bib99","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib100","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jtho.2016.04.028_bib101","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1055-3207(03)00045-0","article-title":"A\u00a0review of peritoneal mesothelioma at the Washington Cancer Institute","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.jtho.2016.04.028_bib102","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/bjc.2012.245","article-title":"Prognosis and prognostic factors of patients with mesothelioma: a population-based study","volume":"107","author":"van der Bij","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib103","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/PAT.0000000000000181","article-title":"Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients","volume":"46","author":"Liu","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.jtho.2016.04.028_bib104","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1517\/13543784.2013.816281","article-title":"Therapies currently in phase II trials for malignant pleural mesothelioma","volume":"22","author":"Pinton","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jtho.2016.04.028_bib105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncponc1039","article-title":"Advances in the systemic therapy of malignant pleural mesothelioma","volume":"5","author":"Fennell","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib106","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib107","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/JTO.0b013e3181ae26ae","article-title":"The mesothelioma and radical surgery randomized controlled trial: the Mars feasibility study","volume":"4","author":"Treasure","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib108","doi-asserted-by":"crossref","first-page":"e0145039","DOI":"10.1371\/journal.pone.0145039","article-title":"Determinants of survival in malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study of 14,228 patients","volume":"10","author":"Taioli","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2016.04.028_bib109","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/JTO.0b013e3182208e3f","volume":"6","author":"Rice","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.lungcan.2013.04.019","article-title":"Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections","volume":"81","author":"Bolukbas","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib111","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2016.04.028_bib112","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jtcvs.2014.03.011","article-title":"Malignant pleural mesothelioma and the Society of Thoracic Surgeons database: an analysis of surgical morbidity and mortality","volume":"148","author":"Burt","year":"2014","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2016.04.028_bib113","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2009.08.019","article-title":"Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin\/pemetrexed and radiotherapy","volume":"71","author":"Bolukbas","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib114","first-page":"428","article-title":"Systematic review of trimodality therapy for patients with malignant pleural mesothelioma","volume":"1","author":"Cao","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2016.04.028_bib115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","article-title":"Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"27","author":"de Perrot","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib116","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib117","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jtcvs.2013.01.039","article-title":"The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11\u201314, 2012, Boston, Mass","volume":"145","author":"Rusch","year":"2013","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2016.04.028_bib118","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1183\/09031936.00039510","article-title":"Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial","volume":"36","author":"Van Schil","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2016.04.028_bib119","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib120","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-13-22","article-title":"Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma","volume":"13","author":"Federico","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib121","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","article-title":"Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"18","author":"Weder","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib122","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.lungcan.2005.03.015","article-title":"Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience","volume":"49 Suppl 1","author":"Flores","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib123","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO.2004.10.071","article-title":"Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"22","author":"Weder","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib124","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2007.02.004","article-title":"Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results","volume":"57","author":"Rea","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.04.028_bib125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ejcts.2006.01.015","article-title":"Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"29","author":"Opitz","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2016.04.028_bib126","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1556-0864(15)31583-5","article-title":"Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial","volume":"1","author":"Flores","year":"2006","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib127","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JTO.0b013e31816fca1b","article-title":"Trimodality treatment of malignant pleural mesothelioma","volume":"3","author":"Batirel","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib128","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2016.04.028_bib129","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2016.04.028_bib131","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib132","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2016.04.028_bib133","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/jco.2015.33.15_suppl.7565","article-title":"Mesothelin-targeted\u00a0immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM)","volume":"33","author":"Hassan","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib134","doi-asserted-by":"crossref","first-page":"CT103","DOI":"10.1158\/1538-7445.AM2015-CT103","article-title":"Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028","volume":"75","author":"Alley","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib135","unstructured":"AstraZeneca. AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2016\/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html. Accessed June 14, 2016."},{"key":"10.1016\/j.jtho.2016.04.028_bib136","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib137","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.028_bib138","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.18632\/oncotarget.3765","article-title":"Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors","volume":"6","author":"Sacco","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2016.04.028_bib139","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jhazmat.2014.05.060","article-title":"The zeta potential of mineral fibres","volume":"276","author":"Pollastri","year":"2014","journal-title":"J\u00a0Hazard Mater"},{"key":"10.1016\/j.jtho.2016.04.028_bib140","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/JTO.0000000000000506","article-title":"The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from Southern Nevada","volume":"10","author":"Baumann","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.028_bib141","series-title":"Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis and Translational Therapy","first-page":"821","article-title":"Economic aspects of mesothelioma","author":"Lagnese","year":"2005"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416304555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416304555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T12:41:19Z","timestamp":1568205679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086416304555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":141,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1556086416304555"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.04.028","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus Report of the 2015 Weinman International Conference on Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2016.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}